RESUMO
BACKGROUND: COVID-19 pandemic had tremendously affected all the aspects of human life during the past 3 years. In this study, we focused on kidney transplant patients' course from the COVID-19 diagnosis, immunosuppressive medication modification, hospitalization, and COVID-19 complications and how the COVID-19 infection affected the kidney and patients' quality of life during the hospitalization and after the discharge. MATERIAL AND METHOD: A retrospective analysis of a prospectively collected database of all kidney transplants adult patients who had a positive COVID-19 PCR from 1 January 2020 to 30 December 2022, and had a history of kidney transplant at the SUNY Upstate Medical Hospital was done to identify the cases. RESULTS: 188 patients met the inclusion criteria and were included in the study. Based on the immunosuppressive regimen modification during COVID-19 infection, patients divided into two groups; in 143 (76%) patients, the immunosuppressive medication was reduced, and in 45 (24%) of patients, the immunosuppressive regimen continued as before during the COVID-19 infection. The mean time from the transplant to the diagnosis of COVID-19 was 67 months in the group we reduced the IM regimen, and 77 months in the group without changes in IM regimen. The mean recipients' age was 50.7 ± 12.9 years in the group we reduced the IM regimen, and 51.8 ± 16.4 years in the group without changes in IM regimen (P = 0.64). The vaccination rate against COVID-19 with at least 2 doses of either the CDC recommended Moderna or Pfizer vaccines was 80.2% in the group we reduced the IM regimen, and 84.8% in the group without changes in IM regimen (P = 0.55). The hospitalization rate due to COVID-19 related symptoms was 22.4% % in the group we reduced the IM regimen, and 35.5% in the group without changes in IM regimen (P = 0.12). However, the ICU admission rate was higher in the group we reduced the IM regimen, but the difference was not significant (26.5% Vs.6.25%, P = 0.12). 6 episodes of biopsy-proven rejection in the group with IM reduction was observed, which were 3 episodes of acute antibody-mediated rejections (ABMR) and 3 episodes of acute T-Cell-mediated rejections (TCMR), and 3 episodes in the group without any change in IM regimen, which were 2 episodes of ABMR and 1 episode of TCMR (P = 0.51). No significant difference was mentioned in the eGFR and serum creatinine after the comparison between the groups after 12 months of follow up. 124 patients responded to the post-COVID-19 questionnaires and were included in the data analysis. The response rate was 66%. Fatigue and exertion were the most reported symptom with a 43.9% prevalence. CONCLUSIONS: We found that immunosuppressive regimen minimization did not impact the kidney function in the long-term and it might be a helpful strategy to minimize the effect of COVID-19 infection on patients' condition during the hospital stay. With all the treatments, vaccinations, and precautions, still some patients did not achieve the complete recovery compared to their pre-COVID-19 health status. Fatigue was the main reported symptom amongst all the reported symptoms.
RESUMO
OBJECTIVES: Given the shortage of kidney donations relative to the ever-increasing demand, there is an ongoing need to utilize available donor organs efficiently and fairly. The purpose of the deceased donor Kidney Allocation System is to optimize and equalize organ access for candidates nationwide. We investigated the outcomes of kidney transplant cases before and after the new allocation placement in March 2021 and the effect of the new allocation system on these outcomes. MATERIALS AND METHODS: We retrospectively reviewed the medical records of the recipients. Outcomes in recipients of renal allografts were compared before and after the changes in March 2021 to the Kidney Allocation System. RESULTS: There were 333 (73.7%) renal allografts transplanted before the 2021 new allocation, and 119 (26.3%) recipients received their renal allografts after the new allocation. The rate of delayed graft function was 33.3% in the preallocation group and 38.65% in the postallocation group (P = .29). The rate for patient readmission within 30 days was compared between the groups and did not show a statistically significant difference (37.8% vs 39.5%; P = .75). The 1-year graft survival rate was 97.5% in the postallocation group and 95.5% in the preallocation group (P = .526). The 1-year patient survival rate was 98.3% in the postallocation group and 95.8% in the preallocation group (P = .499). CONCLUSIONS: This study provides reassurance in finding no statistically significant differences between patient outcomes before and after the implementation of the March 2021 change to the Kidney Allocation System. However, the new allocation measures would help for a more equal distribution of the kidneys.
